Integration of noninvasive prenatal prediction of fetal blood group into clinical prenatal care

32 Citations (Scopus)

Abstract

Incompatibility of red blood cell blood group antigens between a pregnant woman and her fetus can cause maternal immunization and, consequently, hemolytic disease of the fetus and newborn. Noninvasive prenatal testing of cell-free fetal DNA can be used to assess the risk of hemolytic disease of the fetus and newborn to fetuses of immunized women. Prediction of the fetal RhD type has been very successful and is now integrated into clinical practice to assist in the management of the pregnancies of RhD immunized women. In addition, noninvasive prediction of the fetal RhD type can be applied to guide targeted prenatal prophylaxis, thus avoiding unnecessary exposure to anti-D in pregnant women. The analytical aspect of noninvasive fetal RHD typing is very robust and accurate, and its routine utilization has demonstrated high sensitivities for fetal RHD detection. A high compliance with administering anti-D is essential for obtaining a clinical effect. Noninvasive fetal typing of RHC/c, RHE/e, and KEL may become more widely used in the future.

Original languageEnglish
JournalPrenatal Diagnosis
Volume34
Issue number5
Pages (from-to)409-15
Number of pages7
ISSN0197-3851
DOIs
Publication statusPublished - May 2014

Fingerprint

Dive into the research topics of 'Integration of noninvasive prenatal prediction of fetal blood group into clinical prenatal care'. Together they form a unique fingerprint.

Cite this